Position in APGE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$13,273,000
+$4,856,000 QoQ
Shares Held
100,000
0.0% QoQ
Ownership
0.132%
of shares outstanding
% of Portfolio
0.54%
of 13F equity value
Holder Rank
#75
of 285 holders
Holding Since
Sep 2023
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in APGE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026SEVEN GRAND MANAGERS, LLC holds $220,302,823 across 50 Biotechnology names. APGE ranks #4 (6.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SYRE |
Spyre Therapeutics, Inc.
|
225,000 | $19,975,500 | |
| 2 | NKTR |
Nektar Therapeutics
|
240,000 | $16,754,400 | |
| 3 | MANE |
Veradermics, Inc
|
125,000 | $15,367,500 | |
| 4 | APGE |
Apogee Therapeutics, Inc.
This page
|
100,000 | $13,273,000 | |
| 5 | ABVX |
Abivax S.A.
|
90,000 | $11,993,400 | |
| 6 | DFTX |
Definium Therapeutics, Inc.
|
225,000 | $10,584,000 | |
| 7 | ORKA |
Oruka Therapeutics, Inc.
|
110,000 | $10,468,700 | |
| 8 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
100,000 | $9,748,000 |
All Filings in APGE
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $13,273,000 | 100,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $8,417,000 | 100,000 | Shares | Sole | 2026-05-06 | |
| 2025-12-31 | $3,774,000 | 50,000 | Shares | Sole | 2026-02-10 | |
| 2023-09-30 | $1,026,617 | 48,198 | Shares | Sole | 2023-11-14 | |
| No filing history on record for this holder in this stock. | ||||||